Vimian’s Interim Report for the second quarter of 2026

• Revenue increased by 17 per cent to EUR 121.6m (104.3) with organic growth of 12 per cent
• Adjusted EBITA increased 17 per cent to EUR 29.7m (25.4) corresponding to a margin of 24.5 per cent (24.3)
• Operating profit (EBIT) of EUR 22.3m (14.5)
• Profit for the period of EUR 8.8m (8.6) and earnings per share before and after dilution EUR 0.02 (0.02)
• Cash flow from operating activities of EUR 3.8m (22.2)

“Vimian delivered a strong second quarter with strong revenue and earnings growth, and improved margin. Total revenues grew 17 per cent to EUR 121.6 million with organic growth of 12 per cent, ahead of the overall animal health market”, says Alireza Tajbakhsh, CEO Vimian Group, and continues:

“Adjusted EBITA grew 17 per cent to EUR 29.7 million with strong performance across all four segments. The adjusted EBITA margin reached 24.5 per cent, mainly driven by improved profitability in the MedTech segment”.

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q2-report-2026/dial-in

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q2-report-2026

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.